On May 23, 2025, Moleculin Biotech, Inc. received a warning from Nasdaq for not meeting the $2.5 million stockholders' equity requirement, but they have 45 days to submit a compliance plan. No immediate impact on their stock listing, yet future compliance is uncertain.